Loading stock data…
TWST
$99.84+3.19 (+3.30%)
Market ClosedLast close Jun 26
Twist Bioscience Corporation manufactures and sells synthetic DNA-based products.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Twist Bioscience Corporation in the Healthcare sector is trading at $99.84 with a market capitalization of $5.3B. Wall Street consensus targets $74.10 (10 analysts), implying a -25.8% move over the next 12 months. The stock is currently near its 52-week high of $104.23, remaining 122.7% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply -25.8% downside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $110.72M↑ | $103.70M↑ | $99.01M↑ | $96.06M↑ | $92.79M |
| Gross Profit | $57.12M↑ | $53.97M↑ | $50.84M↓ | $51.30M↑ | $46.03M |
| Operating Income | -$38.66M↓ | -$33.10M↓ | -$29.93M↑ | -$30.12M↑ | -$41.56M |
| Net Income | -$44.02M↓ | -$30.51M↓ | -$27.14M↓ | $20.39M↑ | -$39.33M |
Peer Comparison
JNJUNHPFE
Fundamentals
Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, an...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$5.33B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-17.86%
Volume
Today's trading volume
4.28M
Recent News
Investor’s Favored Twist Bioscience’s (TWST) Association with Technology Companies
Osterweis Capital Management, an investment management firm, released its Q1 2026 investor update for its “Osterweis Opportunity Fund”. A copy of the letter can be downloaded here. The fund returned -3.78% in the quarter compared to -2.81% for the Russell 2000 Growth Index. The fund’s long-term returns stay positive, but recent geopolitical shocks and AI […]
The Next Wave of Medical AI Could Mint More Millionaires Than the First -- Here Are the Stocks to Own
AI's next winners in healthcare could be companies like Eli Lilly and Twist Bioscience.
Twist Bioscience (TWST) Stock Could Be 25.5% Overvalued After Its Recent Rally
Twist Bioscience (TWST) stock has attracted fresh attention after a recent move that left shares around $80.79, inviting investors to reassess the company’s synthetic DNA business and current valuation signals. See our latest analysis for Twist Bioscience. The recent move to $80.79 caps a sharp period of momentum, with a 30 day share price return of 64.31% and year to date share price return of 149.43%. The 1 year total shareholder return of 130.57% and 3 year total shareholder return of...
X-Energy (XE) Powers 13.5% as Cathie Wood Gobbles More Stake
X-Energy Inc. (NASDAQ:XE) is one of the 10 Stocks Stealing the Spotlight from Wall Street Giants. X-Energy saw its share prices increase by 13.50 percent on Monday to end at $21.10 apiece, mirroring the broader market optimism and Cathie Wood’s increased exposure to its stock. Last week, Wood’s global asset management, ARK Invest, announced that […]
Cathie Wood Buys $444 Million in SpaceX, Dumps Tesla and AMD
Cathie Wood Dumps Tesla. Her New Favorite Is SpaceX